Song Ruilin: Hengqin "prescription" for innovative development of pharmaceutical industry

The picture shows song Ruilin, executive chairman of China pharmaceutical innovation promotion association China net / China development portal (reporter Wang Donghai) "the pharmaceutical industry led by innovation is undergoing a leap forward development, and China's pharmaceutical industry is facing new changes Chinese medicine needs to propose and develop 3-5 breakthrough new drug R & D technologies, marked by the R & D of 5-10 original new drugs and the international listing In 2035, Chinese medicine will be in the forefront of innovative countries " On August 21, song Ruilin, executive chairman of China pharmaceutical innovation promotion association, said at the China Pharmaceutical Industry Investment Summit of crossdoor financial week Song Ruilin pointed out that pharmaceutical innovation reflects a country's innovation ability and systematic industrial ability All major international innovation regions have promoted pharmaceutical innovation to a strategic level "From the report released by Deloitte, we can see that the average cost of new drug research and development increased from US $1.188 billion in 2010 to US $2.168 billion in 2018 From screening compounds to the final successful listing, including the cost of all failed attempts, all accounted for in the cost of the whole new drug research and development process So we have repeatedly called on the whole society to be tolerant of drug developers and drug pricing " Song Ruilin said that at present, countries are speeding up the approval of new drugs In new drug research and development, the service efficiency of the government also determines the success rate of new drug research and development At the same time, more and more emphasis is put on open innovation He said that the intensity of investment in pharmaceutical industry and scientific and technological innovation and research and development in China is constantly increasing Chinese enterprises pay more and more attention to R & D and take the road of innovation Local pharmaceutical companies are rising, and Chinese pharmaceutical companies are improving their value on the road of drug research and development Finally, one belt, one road, was put forward by Song Ruilin He first gave the "prescription" to Hengqin, which was held in financial week First, Hengqin should use Macao's connections with the Portuguese speaking countries to help China's drugs and go out through the "one belt and one road" At the same time, the establishment of a drug certification platform between China and the European Union makes Portugal a turning point for Chinese drug companies to lead to Europe Second, Hengqin can establish a platform for mutual declaration and service trade between Chinese drugs and European drugs, become a channel for drug trade between China and Europe, and realize entrepot trade and offshore trade Third, establish an international drug intellectual property evaluation and trading center Fourth, we need to move forward with traditional Chinese medicine and build a standard and Evaluation Center for natural drugs Hengqin should play a maximum role in setting standards China's China financial weekly one belt, one Road International Association, the Macao International Association of Chinese thinkers and the Macao Association of Chinese enterprises, the Hengqin New District Financial Services Bureau, Hengqin New District Financial Service Center, Hengqin New District Financial Industry Association Co sponsored by the international social science think tank of Zhuhai, the Chinese Academy of Social Sciences, and the international financial intelligence association of Hengqin district.